Liniment Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 13-12-2024
- Paid Up Capital ₹ 0.24 M
as on 13-12-2024
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 79.16%
(FY 2022)
- Profit -45.19%
(FY 2022)
- Ebitda -43.37%
(FY 2022)
- Net Worth 593.58%
(FY 2022)
- Total Assets 78.29%
(FY 2022)
About Liniment Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.24 M, as per Ministry of Corporate Affairs (MCA) records.
Rohit Bafna, Aastha Dusad, and Rahul Gautam serve as directors at the Company.
- CIN/LLPIN
U24304RJ2018PTC060344
- Company No.
060344
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Feb 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media
- Apps
Who are the key members and board of directors at Liniment Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aastha Dusad  | Director | 26-Feb-2018 | Current |
| Rohit Bafna | Director | 26-Feb-2018 | Current |
| Rahul Gautam | Director | 05-Nov-2019 | Current |
Financial Performance of Liniment Pharma.
Liniment Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 79.16% increase. The company also saw a substantial fall in profitability, with a 45.19% decrease in profit. The company's net worth Soared by an impressive increase of 593.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Liniment Pharma?
In 2022, Liniment Pharma had a promoter holding of 73.97% and a public holding of 26.03%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aldia Lifescience Private LimitedActive 1 year 6 monthsRohit Bafna and Rahul Gautam are mutual person
- United Suppliers Solutions Private LimitedActive 3 years 4 months
Rohit Bafna and Aastha Dusad are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Liniment Pharma?
Liniment Pharma has a workforce of 10 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Liniment Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Liniment Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
